eliglustat tartrate for the treatment of adults with type 1 gaucher disease [corrigendum]
Clicks: 16
ID: 223869
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
4.5
/100
16 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #71 of 73 articles by views in digest journal of nanomaterials and biostructures
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Bennett LL, Turcotte K. Drug Des Devel Ther. 2015;9:4639–4647.On page 4642, left column, 2nd word, the drug name Cardelga® should have been Cerdelga®.On page 4643, Table 2, the drug name Cardelga® should have been Cerdelga®.Read the original article
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (42 words).
Try re-searching for a better abstract.
| Reference Key |
ll2015drugeliglustat
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Bennett LL;Turcotte K |
| Journal | digest journal of nanomaterials and biostructures |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.